4.7 Article

Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6

Andrew W. Chung et al.

Summary: Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have poor response to chemotherapy, while patients with basal-like 1 (BL1) subtype show the best clinical response. Docetaxel activates the MAPK pathway in MSL TNBCs, leading to the release of IL-6 through an IL-1A mediated cascade. Treatment with the humanized IL-6R antibody tocilizumab delays tumor progression in MSL TNBCs.

NPJ BREAST CANCER (2022)

Review Medicine, General & Internal

Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches

Silvia Grassilli et al.

Summary: miR-29b has a controversial role in breast cancer, acting both as a tumor suppressor and as an onco-miRNA. The different isoforms of miR-29b have a dual effect on breast tumor features, depending on the prevailing function, mature miR-29b expression, and breast tumor characteristics. miR-29b-3p and miR-29b1-5p play distinct roles in breast tumors with different phenotypes.

DIAGNOSTICS (2022)

Article Biochemistry & Molecular Biology

FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis

Ying Song et al.

Summary: The study reveals that FOXO3a suppresses breast cancer metastasis by regulating miR-29b-2 and miR-338 to inhibit VEGF-A/NRP1 signaling pathway. This finding proposes a novel therapeutic target for breast cancer treatment.

ONCOGENE (2021)

Article Biochemistry & Molecular Biology

Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function

Kirsteen J. Campbell et al.

Summary: MCL-1 plays a crucial role in breast cancer, with its anti-apoptotic function being key. Deletion or inhibition of MCL-1 relies on pro-apoptotic proteins BAX/BAK for its anti-tumor effects, and it also influences stem cell activity in breast cancer cells.

CELL DEATH AND DIFFERENTIATION (2021)

Article Oncology

Targeting the Vav1/miR-29b axis as a potential approach for treating selected molecular subtypes of triple-negative breast cancer

Silvia Grassilli et al.

Summary: The study revealed that Vav1 is essential for the recovery of mature miR-29b in breast cancer cells and promotes miRNA expression in the mesenchymal molecular subtype of TNBC by sustaining the transcription of the miR-29b1/a cluster. These results indicate that Vav1 may play a crucial role as a modulator of miR-29b expression in breast tumor cells.

ONCOLOGY REPORTS (2021)

Article Oncology

Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma

Yuto Hozaka et al.

Summary: The miR-29-3p family demonstrates tumor-suppressive functions in intrahepatic cholangiocarcinoma (ICC) by targeting key molecules involved in oncogenic pathways such as ITGA6, ITGB1, and SP1. This suggests that miR-29-3p family members could serve as potential therapeutic targets for ICC treatment. The study highlights the importance of exploring microRNA-based strategies in identifying new therapeutic approaches for ICC.

CANCERS (2021)

Article Oncology

Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells

Penn Muluhngwi et al.

Summary: Despite improvements in treating endocrine-resistant metastatic diseases using combination therapies, the mechanisms underlying endocrine resistance are still unclear. Non-coding RNAs, such as miRNA and lncRNA, have been shown to play a role in cell signaling pathways and metastasis. This study identified miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, offering new insights into potential therapeutic targets.

CANCERS (2021)

Article Cell Biology

miR-29b-3p Increases Radiosensitivity in Stemness Cancer Cells via Modulating Oncogenes Axis

Dong Pan et al.

Summary: This study investigated the effects of miR-29b-3p on the radiosensitivity of 3D cultured stem-like cells, finding that its downregulation increased radioresistance, while high expression showed advantages in patient prognosis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Cell Biology

New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin

Cristina Alexandra Ciocan-Cartita et al.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)

Article Oncology

New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells

Cristina Alexandra Ciocan-Cartita et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

Review Biochemistry & Molecular Biology

A Looking-Glass of Non-Coding RNAs in Oral Cancer

Alexandra Iulia Irimie et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Article Medicine, General & Internal

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies

Carsten Denkert et al.

LANCET (2017)

Article Multidisciplinary Sciences

The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells

Penn Muluhngwi et al.

SCIENTIFIC REPORTS (2017)

Review Medicine, General & Internal

Tumor Heterogeneity in Breast Cancer

Gulisa Turashvili et al.

FRONTIERS IN MEDICINE (2017)

Review Obstetrics & Gynecology

An overview of triple-negative breast cancer

Pankaj Kumar et al.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2016)

Article Biochemistry & Molecular Biology

DIANA-miRPath v3.0: deciphering microRNA function with experimental support

Ioannis S. Vlachos et al.

NUCLEIC ACIDS RESEARCH (2015)

Article Oncology

MiR-886-5p Inhibition Inhibits Growth and Induces Apoptosis of MCF7 Cells

Lei-Lei Zhang et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)

Article Oncology

Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment

Ioana Berindan-Neagoe et al.

CLINICAL CANCER RESEARCH (2014)

Article Pharmacology & Pharmacy

NCRNA Combined Therapy as Future Treatment Option for Cancer

Cornelia Braicu et al.

CURRENT PHARMACEUTICAL DESIGN (2014)

Review Medicine, Research & Experimental

Heterogeneity in breast cancer

Kornelia Polyak

JOURNAL OF CLINICAL INVESTIGATION (2011)

Review Biochemistry & Molecular Biology

MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy

William C. S. Cho

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)